Entries by tag: bones
Not sure what to make of this:
http://altering-perspectives.com/2014/02/dna-analysis-elongated-skull-released-results-incredible.html
Sounds like the creatures who had elongated hominid skulls found in Peru were genetically quite different from homo sapiens.
http://altering-perspectives.com/2014/02/dna-analysis-elongated-skull-released-results-incredible.html
Sounds like the creatures who had elongated hominid skulls found in Peru were genetically quite different from homo sapiens.
sites for assessing micronutrient contents of food
www.nal.usda.gov/fnic/foodcomp/search/
www.nutritiondata.com
( our last nutrition I lecture with professor Gerber, moved forward from same date 2009, already got thyroid, anemia bitsCollapse )
www.nal.usda.gov/fnic/foodcomp/search/
www.nutritiondata.com
( our last nutrition I lecture with professor Gerber, moved forward from same date 2009, already got thyroid, anemia bitsCollapse )
1000 on Ca+ only-->6 more MI's or strokes and 3 less fractures
( data from the Women's Health Initiative added to the meta-analysis of cardiovascular risks associated with calcium supplementsCollapse )
( data from the Women's Health Initiative added to the meta-analysis of cardiovascular risks associated with calcium supplementsCollapse )
http://www.medscape.com/viewarticle/735066?src=mp&spon=22
Vitamin D deficiency occurs more frequently in patients with primary hyperparathyroidism (PHPT) compared with the general population, and is usually associated with an aggravated form of the disease. Current guidelines recommend measurement of serum levels of 25-hydroxy vitamin D (25-OHD) in all patients with PHPT, and their repletion if the levels are less than 50 mmol/L (20 ng/mL). Limited data suggest that vitamin D treatment is generally safe in subjects with mild PHPT and coexisting vitamin D deficiency. Adverse effects include hypercalcuria and, less commonly, exacerbation of hypercalcemia. Well-designed trials are needed to evaluate the safety of vitamin D replacement therapy in a wide spectrum of patients with concomitant PHPT and vitamin D deficiency. These trials should address the impact of such therapy on the complications and course of PHPT.
Vitamin D deficiency occurs more frequently in patients with primary hyperparathyroidism (PHPT) compared with the general population, and is usually associated with an aggravated form of the disease. Current guidelines recommend measurement of serum levels of 25-hydroxy vitamin D (25-OHD) in all patients with PHPT, and their repletion if the levels are less than 50 mmol/L (20 ng/mL). Limited data suggest that vitamin D treatment is generally safe in subjects with mild PHPT and coexisting vitamin D deficiency. Adverse effects include hypercalcuria and, less commonly, exacerbation of hypercalcemia. Well-designed trials are needed to evaluate the safety of vitamin D replacement therapy in a wide spectrum of patients with concomitant PHPT and vitamin D deficiency. These trials should address the impact of such therapy on the complications and course of PHPT.
congenital = present at birth
hereditary = inherited
familial = runs in family
genetic = caused by gene
reduced penetrance often at work in dominant diseases: genotype does not "penetrate" to phenotype
( notes on osteogenesis imperfecta, neurofibromatosis, achondroplasia, marfan syndrome, polycystic kidney diseaseCollapse )
hereditary = inherited
familial = runs in family
genetic = caused by gene
reduced penetrance often at work in dominant diseases: genotype does not "penetrate" to phenotype
( notes on osteogenesis imperfecta, neurofibromatosis, achondroplasia, marfan syndrome, polycystic kidney diseaseCollapse )
Comments